Drug details

Rukobia (fostemsavir extended-release tablets)

type of HIV, Attachment Inhibitors

Rukobia (fostemsavir), is a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor, used in combination with other antiretroviral(s), to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

The drug is often used to treat HIV .

This drug may have the following side effects:

• nausea,
• rash,
• diarrhea,
• headache,
• fatigue,
• vomiting
• abdominal pain,
• indigestion/heartburn,
• drowsiness, and
• sleep disturbance,
• immune reconstitution inflammatory syndrome,

The following drugs are related to Rukobia, either as a replacement or used together:

• Ziagen (abacavir sulfate)
• Epzicom (abacavir sulfate and lamivudine tablets)
• Trizivir (abacavir sulfate, lamivudine, and zidovudine)
• Apretude (cabotegravir extended-release injectable suspension)
• Evotaz (atazanavir and cobicistat tablets for oral administration)
• Reyataz (atazanavir sulfate)
• Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide tablets)
• Cabenuva (cabotegravir; rilpivirine extended-release injectable suspension)
• Vocabria (cabotegravir tablets for oral use)
• Prezista (darunavir)
• Prezcobix (darunavir and cobicistat tablets)
• Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir  alafenamide tablets)
• Rescriptor (delavirdine mesylate)
• Videx EC (didanosine delayed-release capsules)
• Videx (didanosine pediatric powder for oral solution)
• Tivicay (doutegravir 50mg tablets)